Core Insights - Knight Therapeutics Inc. reported record-high quarterly revenues of $107,358, an increase of 12% compared to the same period last year, driven by key promoted products and acquisitions [7][16][10] - The company has increased its financial guidance for 2025, now expecting revenues between $410 million to $420 million, up from a previous estimate of $390 million to $405 million [48] Financial Results - Revenues for Q2-25 were $107,358, up $11,785 or 12% year-over-year, with adjusted revenues at $108,541, reflecting a 15% increase [7][72] - Gross margin decreased to 42% of revenues from 50% in Q2-24, primarily due to hyperinflation accounting impacts in Argentina [7][23] - Operating loss was $3,669 compared to an operating income of $4,494 in the same period last year, while net loss increased to $12,622 from $1,942 [7][27] - Cash inflow from operations was $20,252, a significant improvement from cash outflows of $1,086 in the prior year [7] Corporate Developments - The company entered into a revolving credit facility of US$50,000 with National Bank of Canada, with $60,000 withdrawn to fund part of the Paladin acquisition [7][46] - Knight completed the acquisition of Paladin Pharma Inc. for $106,885, including $22,341 for inventory, and may pay additional contingent payments based on sales milestones [7][43] - The company also entered into exclusive license and supply agreements with Sumitomo for several products, including Myfembree and Orgovyx, with an upfront payment of $25,400 [7][44] Product Updates - Knight submitted Crexont for regulatory approval in Canada and Mexico, and Minjuvi for approval in Brazil for follicular lymphoma [36][38] - The company obtained regulatory approval for Pemazyre in Argentina and Rembre in Chile [35][7] Market Performance - The innovative product portfolio delivered organic growth of 15% on a constant currency basis during the first half of 2025 [10] - The therapeutic area revenues showed varied performance, with oncology/hematology down 4%, infectious diseases up 17%, and other specialty up 32% year-over-year [17][20][21]

Financial Results - Revenues for Q1-25 were $88,076, an increase of $1,472 or 2% compared to Q1-24, driven by growth in key promoted products, partially offset by declines in mature products and currency depreciation in select LATAM countries [7][13] - Gross margin decreased to $34,866 or 40% of revenues from $41,699 or 48% in the same period last year, primarily due to hyperinflation accounting in Argentina [7][19] - Operating loss was $5,537 compared to an operating income of $2,660 in Q1-24 [11][25] - Net income was $2,185, a significant improvement from a net loss of $4,546 in the prior year [25] - Adjusted revenues were $87,979, reflecting a 3% increase, and $6,631 or 8% on a constant currency basis [7][13] Corporate Developments - The company entered into an asset purchase agreement to acquire the Paladin business for $100,000, with an additional $20,000 for inventory, and potential future payments of up to $15,000 based on sales milestones [7][36] - A working capital line of credit of USD 40,000 was obtained from Citibank, with USD 35,000 withdrawn [6][37] - The company in-licensed Onicit IV for distribution in Mexico, Brazil, and select LATAM countries, and submitted Tavalisse for ANMAT approval in Argentina [8][33][35] Shareholder Updates - Shareholders re-elected members to the Board of Directors, including Jonathan Ross Goodman and Samira Sakhia [9] Financial Outlook - The company reaffirmed its financial guidance for 2025, expecting revenues between $390 million to $405 million and adjusted EBITDA to be approximately 13% of revenues [38]